# Elite Technology-Transfer Dossier — P-22

**Generated:** 2026-08-26T05:28:02.190370+00:00
**Schema:** ELITE_TECHNOLOGY_TRANSFER_DOSSIER_v1
**Three axes:** T1 / DECISIVE_EXPERIMENT_REQUIRED / UNCONTACTED
**Buyer truth:** A computationally specified P-22 concept plus a preregistered decisive experiment — not a validated technology.
**Not a patent court:** True

---

## 01 — Buyer Decision Card

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BUYER DECISION CARD
P-22
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**TECHNOLOGY**
P-22 — Multi-segment shape-memory polymer catheter with autonomous navigation toward op

**WHY YOU MAY CARE**
A computationally specified P-22 concept plus a preregistered decisive experiment — not a validated technology.

**CURRENT EVIDENCE**
  Technical readiness: T1
  Physical validation: NONE
  Transfer posture: DECISIVE_EXPERIMENT_REQUIRED

**WHAT IS NOT PROVEN**
  - Buckling: catheter WILL buckle before reaching actuation force limit (82x exceedance)
  - Control stability NOT modeled (30s delay makes PID unstable)
  - Tissue safety: effective force 0.039 N exceeds estimated damage threshold 0.01 N by 4x

**STRONGEST ALTERNATIVE**
  Intraoperative placement (surgeon-dependent). Published steerable catheters use closed-loop control + sensing + passive safety (PubMed 25684857).

**DECISIVE QUESTION**
  Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?

**COST TO ANSWER**
  $15-30K (ESTIMATED: SMP prototype + tissue phantom + force sensors)

**TIME**
  8-12 weeks (ESTIMATED: prototype + testing)

**IF PASS**
  Advance to next development phase (see Development Plan)

**IF FAIL**
  Repair / redesign / terminate (see Failure Record)

**WHAT WE ARE ASKING YOU TO DO**
  COMMISSION TEST — build SMP segment + tissue phantom, measure navigation + buckling + tissue force. CURRENT STATUS: HIGH-RISK CONTROL/SAFETY HYPOTHESIS

**BUYER_ACTION_ID**
  P22-EXP-001

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

---

## 02 — Executive Technology Brief

# Executive Technology Brief — P-22

**Reading time target:** 2 minutes

## Problem
Suboptimal catheter placement = 3-5% of shunt failures. Repositioning requires surgery.

## Technology
Multi-segment shape-memory polymer catheter with autonomous navigation toward optimal drainage position

## Potential Advantage
Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?

## Evidence Summary
- Technical readiness: T1
- Transfer posture: DECISIVE_EXPERIMENT_REQUIRED
- T1 — 3 modelled claims, 0 computationally supported

## Remaining Risk
Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?

## Next Action
COMMISSION TEST — build SMP segment + tissue phantom, measure navigation + buckling + tissue force. CURRENT STATUS: HIGH-RISK CONTROL/SAFETY HYPOTHESIS

---
*This is an elite technology-transfer dossier. Every claim traces to evidence. Every uncertainty is explicit. See full dossier for details.*


---

## 03 — Customer / Industrial Problem

- **Exact problem:** Suboptimal catheter placement = 3-5% of shunt failures. Repositioning requires surgery.
- **Affected users:** Catheter manufacturer / interventional device company
- **Frequency:** BUYER_DILIGENCE_REQUIRED — clinical incidence data not in package
- **Current cost:** BUYER_DILIGENCE_REQUIRED — economic model not yet sourced
- **Current workaround:** Intraoperative placement (surgeon-dependent). Published steerable catheters use closed-loop control + sensing + passive safety (PubMed 25684857).
- **Incumbent solutions:** ['Intraoperative placement (surgeon-dependent). Published steerable catheters use closed-loop control + sensing + passive safety (PubMed 25684857).']
- **Why problem remains unsolved:** Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?

---

## 04 — Technology Description

- **Mechanism:** Multi-segment shape-memory polymer catheter with autonomous navigation toward optimal drainage position
- **Architecture:** SEE mechanism field — full architecture requires technical diligence
- **Components:** BUYER_DILIGENCE_REQUIRED
- **Inputs:** BUYER_DILIGENCE_REQUIRED
- **Outputs:** BUYER_DILIGENCE_REQUIRED
- **Operating conditions:** BUYER_DILIGENCE_REQUIRED
- **Diagrams:** NOT_GENERATED — buyer diligence team to request
- **Key equations:** SEE provenance artifacts (model scripts)
- **Dependencies:** BUYER_DILIGENCE_REQUIRED
- **Implementation assumptions:**
  - Buckling: catheter WILL buckle before reaching actuation force limit (82x exceedance)
  - Control stability NOT modeled (30s delay makes PID unstable)
  - Tissue safety: effective force 0.039 N exceeds estimated damage threshold 0.01 N by 4x
  - No failure recovery mechanism

---

## 05 — What Is Actually New?

- **Known prior approaches:** ['Intraoperative placement (surgeon-dependent). Published steerable catheters use closed-loop control + sensing + passive safety (PubMed 25684857).']
- **Limitation of prior:** Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?
- **Our mechanism:** Multi-segment shape-memory polymer catheter with autonomous navigation toward optimal drainage position
- **Difference:** Differentiation hypothesis: Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?
- **Expected advantage:** Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?
- **Note:** Do not say 'novel technology.' Say what existing systems do, what breaks, and how this mechanism changes the failure mode.

---

## 06 — Competitive Alternatives

| Approach | Strength | Weakness | Evidence | Why buyer might choose us |
|----------|----------|---------|----------|---------------------------|
| Intraoperative placement (surgeon-dependent). Published steerable catheters use  | Established clinical track record | BUYER_DILIGENCE_REQUIRED | Published clinical literature | Can a buckling-safe architecture with closed-loop control na |
| P-22 — Multi-segment shape-memory polymer catheter with autonomous  | SEE evidence ledger | Buckling: catheter WILL buckle before reaching actuation for | T1 — see evidence ledger | A computationally specified P-22 concept plus a preregistere |

**Where we lose:**
  - Buckling: catheter WILL buckle before reaching actuation force limit (82x exceedance)
  - Control stability NOT modeled (30s delay makes PID unstable)
  - Tissue safety: effective force 0.039 N exceeds estimated damage threshold 0.01 N by 4x
  - No failure recovery mechanism

*An elite package tells the buyer where the technology currently loses. This is more credible than claiming superiority.*

---

## 07 — Evidence & Validation Ledger

### MODELLED
- **Claim:** Actuation force (MODELLED)
  - Method: internal computational model
  - Source: R329/g5_constrained_hunt/P-22_MANUFACTURING.json + R330/g5_p22_harden/P-22_HARDENED.json + R331/g5_p22_control/P-22_CONTROL_ANALYSIS.json
  - Limitation: model prediction — not experimentally verified
  - Confidence: model-derived
- **Claim:** Buckling limit (MODELLED, Euler)
  - Method: internal computational model
  - Source: R329/g5_constrained_hunt/P-22_MANUFACTURING.json + R330/g5_p22_harden/P-22_HARDENED.json + R331/g5_p22_control/P-22_CONTROL_ANALYSIS.json
  - Limitation: model prediction — not experimentally verified
  - Confidence: model-derived
- **Claim:** Force margin (MODELLED, Stokes drag over-simplified)
  - Method: internal computational model
  - Source: R329/g5_constrained_hunt/P-22_MANUFACTURING.json + R330/g5_p22_harden/P-22_HARDENED.json + R331/g5_p22_control/P-22_CONTROL_ANALYSIS.json
  - Limitation: model prediction — not experimentally verified
  - Confidence: model-derived

### ASSUMED
- **Claim:** FAILED ASSUMPTION: Buckling: catheter WILL buckle before reaching actuation force limit (82x exceedance)
  - Method: internal computational model
  - Source: R329/g5_constrained_hunt/P-22_MANUFACTURING.json + R330/g5_p22_harden/P-22_HARDENED.json + R331/g5_p22_control/P-22_CONTROL_ANALYSIS.json
  - Limitation: this assumption broke — buyer must not rely on it
  - Confidence: high (falsified)
- **Claim:** FAILED ASSUMPTION: Control stability NOT modeled (30s delay makes PID unstable)
  - Method: internal computational model
  - Source: R329/g5_constrained_hunt/P-22_MANUFACTURING.json + R330/g5_p22_harden/P-22_HARDENED.json + R331/g5_p22_control/P-22_CONTROL_ANALYSIS.json
  - Limitation: this assumption broke — buyer must not rely on it
  - Confidence: high (falsified)
- **Claim:** FAILED ASSUMPTION: Tissue safety: effective force 0.039 N exceeds estimated damage threshold 0.01 N by 4x
  - Method: internal computational model
  - Source: R329/g5_constrained_hunt/P-22_MANUFACTURING.json + R330/g5_p22_harden/P-22_HARDENED.json + R331/g5_p22_control/P-22_CONTROL_ANALYSIS.json
  - Limitation: this assumption broke — buyer must not rely on it
  - Confidence: high (falsified)
- **Claim:** FAILED ASSUMPTION: No failure recovery mechanism
  - Method: internal computational model
  - Source: R329/g5_constrained_hunt/P-22_MANUFACTURING.json + R330/g5_p22_harden/P-22_HARDENED.json + R331/g5_p22_control/P-22_CONTROL_ANALYSIS.json
  - Limitation: this assumption broke — buyer must not rely on it
  - Confidence: high (falsified)

---

## 08 — Technical Readiness & Risk

- **Technical readiness:** T1
- **Physical validation:** NONE
- **Manufacturing readiness:** UNKNOWN
- **Integration readiness:** UNKNOWN
- **Regulatory readiness:** UNKNOWN

### Risk Register
| Risk | Probability | Impact | Evidence | Mitigation | Experiment |
|------|------------|--------|----------|------------|------------|
| Mechanism does not survive physical validation | MEDIUM | HIGH | No physical validation performed | Decisive experiment (see Section 10/11) | Bench: SMP catheter segment in tissue ph |
| Manufacturing tolerances exceed design envelope | UNKNOWN | HIGH | No manufacturing tolerance study | BUYER_DILIGENCE_REQUIRED | Manufacturing feasibility study |
| Regulatory pathway more complex than estimated | UNKNOWN | MEDIUM | PMA (active implantable with navigation) | Regulatory consultant review | Pre-submission meeting with FDA |

---

## 09 — Failure & Falsification Record

- **Failed hypotheses:** ['Buckling: catheter WILL buckle before reaching actuation force limit (82x exceedance)', 'Control stability NOT modeled (30s delay makes PID unstable)', 'Tissue safety: effective force 0.039 N exceeds estimated damage threshold 0.01 N by 4x', 'No failure recovery mechanism']
- **Failed models:** None recorded
- **Cemetery rules:** SEE R336/m2_discovery_engine/autonomous_discovery_engine.py CEMETERY_RULES
- **Alternative mechanisms rejected:** SEE cemetery entries (P-14, P-17, P-19, P-23, CE-029)
- **Parameter regimes that fail:** SEE R339/g4_p24_vvuq_decision_boundary for P-24 failure envelope
- **Known boundary conditions:** Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?

*A buyer should think: 'These people have tried to break their own technology.' That's valuable.*

---

## 10 — Remaining Decisive Question

**The question:** Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?

**Decision tree:**
- PASS → Advance toward prototype (see Development Plan Phase 2)
- AMBIGUOUS → Additional experiment required (see Development Plan)
- FAIL → Repair / redesign / terminate (see Failure Record and Cemetery Rules)

- **Pass condition:** Safe closed-loop navigation to target within 5mm accuracy AND tissue force < 0.01 N AND failure recovery demonstrated
- **Fail condition:** Buckling prevents controlled navigation OR tissue force > 0.01 N OR no failure recovery
- **Ambiguous condition:** CI spans pass/fail threshold → AMBIGUOUS (no silent promotion)

---

## 11 — Development & Experiment Plan

### Phase 1 Bench Validation
- Objective: Bench: SMP catheter segment in tissue phantom. Measure: controlled navigation accuracy, buckling behavior, tissue contact force, failure recovery.
- Cost: $15-30K (ESTIMATED: SMP prototype + tissue phantom + force sensors)
- Time: 8-12 weeks (ESTIMATED: prototype + testing)
- Equipment: BUYER_DILIGENCE_REQUIRED
- Expertise: BUYER_DILIGENCE_REQUIRED
- Pass criteria: Safe closed-loop navigation to target within 5mm accuracy AND tissue force < 0.01 N AND failure recovery demonstrated
- Dependencies: None (first phase)

### Phase 2 Prototype
- Objective: Build functional prototype incorporating bench-validated mechanism
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Equipment: BUYER_DILIGENCE_REQUIRED
- Expertise: BUYER_DILIGENCE_REQUIRED
- Pass criteria: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 1 PASS

### Phase 3 Relevant Environment
- Objective: Test in clinically relevant environment (cadaver, animal, or simulated)
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 2 PASS

### Phase 4 Regulatory Validation
- Objective: Regulatory submission and approval
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 3 PASS

### Phase 5 Commercial Deployment
- Objective: Commercial launch and post-market surveillance
- Cost: BUYER_DILIGENCE_REQUIRED
- Time: BUYER_DILIGENCE_REQUIRED
- Dependencies: Phase 4 regulatory approval

---

## 12 — Manufacturing & Integration

- Components: BUYER_DILIGENCE_REQUIRED
- Suppliers: BUYER_DILIGENCE_REQUIRED
- Manufacturing process: BUYER_DILIGENCE_REQUIRED
- Tolerances: BUYER_DILIGENCE_REQUIRED — see VVUQ for parameter sensitivity (P-24: R339/g4)
- Scale-up issues: BUYER_DILIGENCE_REQUIRED
- Integration points: VERY HIGH — SMP in CSF, control system, safety architecture
- Software/hardware dependencies: BUYER_DILIGENCE_REQUIRED
- Estimated engineering effort: BUYER_DILIGENCE_REQUIRED
- Unresolved manufacturing risks: BUYER_DILIGENCE_REQUIRED

*If you licensed this tomorrow, what would you actually have to do? This section must be filled during buyer diligence.*

---

## 13 — Regulatory Diligence

- Known regulatory category: PMA (active implantable with navigation) — very complex
- Known requirements: BUYER_DILIGENCE_REQUIRED
- Unknown requirements: BUYER_DILIGENCE_REQUIRED
- Likely testing: BUYER_DILIGENCE_REQUIRED
- Regulatory dependencies: BUYER_DILIGENCE_REQUIRED
- Specialist review required: Regulatory consultant / FDA pre-submission meeting

*Never claim 'regulatory approved' unless actually approved.*

---

## 14 — IP / Ownership / FTO Diligence

- IP status: BUYER_DILIGENCE_REQUIRED — no patent search performed
- Known disclosures: BUYER_DILIGENCE_REQUIRED
- Known prior art sources: BUYER_DILIGENCE_REQUIRED — see CEREVASC_SLOT5_DISCOVERY for prior art searches
- Ownership: CereVascular (assumed — confirm with CEO)
- Contributors: BUYER_DILIGENCE_REQUIRED
- Third-party technology: BUYER_DILIGENCE_REQUIRED
- License restrictions: UNKNOWN
- Patent search status: NOT_PERFORMED — we are not running a patent court
- FTO status: BUYER_DILIGENCE_REQUIRED — buyer counsel must perform freedom-to-operate analysis
- Counsel review required: Full IP diligence by buyer counsel

*We surface open questions. Buyer counsel performs detailed diligence. We do not render patentability verdicts.*

---

## 15 — Commercialization / Deal Path

**Recommended path:** License to catheter/interventional company (HIGH RISK)

**Options:**

### LICENSE
- what_is_licensed: The P-22 mechanism, architecture, and supporting evidence package
- field_of_use: BUYER_DILIGENCE_REQUIRED
- exclusivity: BUYER_DILIGENCE_REQUIRED
- consideration: BUYER_DILIGENCE_REQUIRED

### CO_DEVELOP
- what_each_party_contributes: CereVascular: mechanism + evidence. Buyer: manufacturing + clinical + regulatory.
- governance: BUYER_DILIGENCE_REQUIRED

### BUILD
- what_buyer_develops: Full productization from mechanism + evidence package
- estimated_effort: BUYER_DILIGENCE_REQUIRED

### ACQUIRE
- what_assets_transfer: All IP, evidence, models, protocols, know-how
- valuation: BUYER_DILIGENCE_REQUIRED — see WIPO valuation guidance (market/cost/income approaches)

### COMMISSION_EXPERIMENT
- cost: $15-30K (ESTIMATED: SMP prototype + tissue phantom + force sensors)
- timeline: 8-12 weeks (ESTIMATED: prototype + testing)
- what_it_decides: Can a buckling-safe architecture with closed-loop control navigate safely without tissue damage?

### REJECT
- evidence_justifying_walking_away: ['Buckling: catheter WILL buckle before reaching actuation force limit (82x exceedance)', 'Control stability NOT modeled (30s delay makes PID unstable)', 'Tissue safety: effective force 0.039 N exceeds estimated damage threshold 0.01 N by 4x', 'No failure recovery mechanism']

**Buyer action:** COMMISSION TEST — build SMP segment + tissue phantom, measure navigation + buckling + tissue force. CURRENT STATUS: HIGH-RISK CONTROL/SAFETY HYPOTHESIS

---

## Validation (Independent)

- Validator independent from generator: True
- Article XXVI compliance: No self-certification
- Q1 (send without verbal): PASS
- Q2 (identify next step): PASS
- Q3 (facts vs hypotheses): PASS
- Q4 (challenge without trusting): PASS